Interní Med. 2009; 11(4): 178-181

Oxidative stress and COPD

MUDr. Norbert Pauk
Klinika pneumologie a hrudní chirurgie, FN Na Bulovce, 3. LF UK Praha, IPVZ Praha

Chronic obstructive pulmonary disease (COPD) is defined by fixed airflow limitation associated with an abnormal pulmonary and systemic

inflammatory response of the lungs to cigarette smoke. A better understanding of the origin and consequences of systemic inflammation

and oxidative stress, and of potential therapies, will most likely lead to better care of patients with COPD. The role of antioxidants

is analysed. The main treatment options are inhaled bronchodilatators and pulmonary rehabilitation with smoking cessation. There are

only limited indications for inhaled glucocorticosteroids.

Keywords: COPD, oxidative stress, antioxidants.

Published: June 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pauk N. Oxidative stress and COPD. Interní Med. 2009;11(4):178-181.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated December 2008; www.goldcopd.com.
    2. Celli BR. Update on the Management of COPD. Chest 2008; 133: 1451-1462. Go to original source... Go to PubMed...
    3. Rabe KF, Hurd S, Anzueto A, et al. Global Strategy for the diagnosis, management, and prevention of COPD: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532-555. Go to original source... Go to PubMed...
    4. Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946. Go to original source... Go to PubMed...
    5. NICE Guideline - COPD 2004. Www.Nice.org.uk/pdf/CG012_niceguideline.pdf
    6. Vondra V, Malý M, Švandová E. Rozborilová E. Úmrtnost na chronickou obstrukční plicní nemoc v ČR a SR v letech 1999-2003. Medicína po promoci 2005; 6: 80-88.
    7. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-1257. Go to original source... Go to PubMed...
    8. Agusti A. Thomas A. Neff lecture. Chronic obstructive pulmonary disease: a systemic disease. Proc Am Thorac Soc 2006; 3: 478-481. Go to original source... Go to PubMed...
    9. Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8-11. Go to original source... Go to PubMed...
    10. Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? Lancet 2007; 370: 797-799. Go to original source... Go to PubMed...
    11. Pauk N. Současné postavení dlouhodobě působících bronchodilatancií v léčbě stabilní chronické obstrukční plicní nemoci. Farmakoterapie 2005; 1: 379-384.
    12. Barnes PJ. Scientific rationale for inhaled combination therapy with long-acting beta2-agonists and corticosteroids. Eur Respir J 2002; 19: 182-191. Go to original source... Go to PubMed...
    13. Barnes PJ. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004; 363: 731-733. Go to original source... Go to PubMed...
    14. Kolek V. Mukolytika - léky nejen proti kašli. Med. Pro Prax 2001; 2: 62-67.
    15. Celli B, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J, 2007; 29: 1224-1238. Go to original source... Go to PubMed...
    16. Kašák V. Chronická obstrukční plicní nemoc. Praha Maxdorf 2006; 187.
    17. Kašák V. Lze modifikovat klinický průběh CHOPN? Medicína po promoci, 2006; 7: 109-114.
    18. Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365 (9470): 1552-1560. Go to original source... Go to PubMed...
    19. Koblížek V, Tomšová M, Lánský M, Salajka F. Mukoaktivní léky (stručný přehled). Stud Pneumol Phtiseol 2007; 67 (1): 18-25.
    20. Pauk N. Současná farmakoterapie stabilizované CHOPN. Farmakoterapie 2008, 1: 75-82.
    21. Pauk N. Současné možnosti léčby CHOPN. Stud. Pneumol. Phthiseol. 2008, 68 (5): 181-188.
    22. Pauk N. Chronický zánět dolních dýchacích cest a CHOPN. Jak spolu souvisejí? Medicína po promoci 2008, 9(5).

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.